Drug maker Lupin on Tuesday said it has received approval from the U.S. health regulator to market a generic medication to treat swelling and pain in the eye.
The company has received approval from the U.S. Food and Drug Administration for Bromfenac Ophthalmic Solution, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Sun Pharma's BromSite Ophthalmic Solution, it added.
Lupin is the exclusive first-to-file for this product, the drug maker said.
Shares of Lupin ended 0.43% higher at Rs 1,579.75 apiece on the BSE.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
